Exact Sciences Falls 3.86% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 6:02PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $11.51 to a high of $12.76. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $12.25 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exact Sciences Announces Successful Completion of Public Offering of Common Stock
Business Wire - Wed Apr 09, 3:05PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced underwritten public offering of its common stock at a price of $12.75 per share to the public.
Stocks Review on Top Gainers -- Research on Genco Shipping & Trading, Exact Sciences, Baltic Trading, and Eagle Bulk Shipping
PR Newswire - Mon Apr 07, 11:38AM CDT
The US markets saw a negative sentiment on Friday, April 4, 2014, with the NASDAQ Composite closing at 4,127.73, down 2.60%, the Dow Jones Industrial Average ending the session at 16,412.71, down 0.96%, and the S&P 500 declining 1.25% to finish the trading session at 1,865.09. The session witnessed selling pressure in the Information Technology, Consumer Discretionary, Health Care, and Materials sectors that negatively impacted the broader market. A number of stocks saw large movements, including Genco Shipping & Trading Ltd (NYSE: GNK), Exact Sciences Corp. (NASDAQ: EXAS), Baltic Trading Ltd (NYSE: BALT) and Eagle Bulk Shipping Inc. (NASDAQ: EGLE). Free technical research on GNK, EXAS, BALT and EGLE can be downloaded upon signing up at:
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Exact Sciences (EXAS) Stock Is Higher On Friday
at The Street - Fri Apr 04, 8:56AM CDT
Shares of Exact Sciences (EXAS) are up 5.30% to $13.60 after the molecular diagnostics company announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public.
Exact Sciences Prices Public Offering of Common Stock
Business Wire - Fri Apr 04, 7:42AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public. The net proceeds to Exact from this offering are expected to be approximately $119.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Exact. The offering is expected to close on or about April 9, 2014, subject to the satisfaction of customary closing conditions. Exact has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Exact anticipates using the net proceeds from the offering to fund its efforts to obtain FDA approval of its Cologuard test, to fund Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes.
Exact Sciences Announces Proposed Public Offering of Common Stock
Business Wire - Wed Apr 02, 3:01PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that it is offering $125 million of shares of its common stock in a proposed underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares will be issued pursuant to a prospectus supplement to be filed as part of a shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3.
Exact Sciences (EXAS) Jumps: Stock Adds 10.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:51AM CDT
Exact Sciences Corporation was a big mover last session, as its shares rose over 10% on the day.
Why Exact Sciences, Builders FirstSource, and Clayton Williams Energy Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:00PM CDT
Over the weekend, investors who tuned into 60 Minutes got a look at the new Michael Lewis book on high-frequency trading, with dire conclusions about how traders take advantage of both institutional and individual investors. Yet even with that...
Today's Dead Cat Bounce Stock Is Exact Sciences Corporation (EXAS)
at The Street - Mon Mar 31, 8:45AM CDT
Trade-Ideas LLC identified Exact Sciences Corporation (EXAS) as a "dead cat bounce" (down big yesterday but up big today) candidate
CBS Outdoor Americas Climbs on First Day of Trading; FDA Advisory Panel Recommends Approval of Exact Sciences Corporation's Cologuard
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
CBS Outdoor Americas Inc. (NYSE: CBSO) - For an in-depth report on CBS Outdoor Americas Inc. follow: www.BullTrends.com/stockquote/CBSO
'Mad Money' Lightning Round: Sell Starbucks at $72
at The Street - Sat Mar 29, 5:00AM CDT
Cramer prefers Boeing over AerCap Holdings and CBS Outdoor over Chambers Street Properties.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Mar 28, 7:21PM CDT
Cramer says the market needs both a China stimulus plan and positive U.S. employment numbers to sustain any gains.
Look for Shares of Exact Sciences to Potentially Rebound after Yesterday's 6.47% Sell Off
Comtex SmarTrend(R) - Fri Mar 28, 4:34PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $12.52 to a high of $14.60. Yesterday, the shares fell 6.5%, which took the trading range below the 3-day low of $13.61 on volume of 9.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exact Sciences Corporation (EXAS) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Fri Mar 28, 11:33AM CDT
Trade-Ideas LLC identified Exact Sciences Corporation (EXAS) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Exact Sciences Announces FDA Advisory Committee Unanimously Recommends Approval of Cologuard
Business Wire - Thu Mar 27, 2:52PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard(R), the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test.
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation, GlaxoSmithKline PLC, a
George Budwell, The Motley Fool - Motley Fool - Thu Mar 27, 8:00AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Exact Sciences' Stock Trading Halted Today; FDA Advisory Committee Meeting to Review Premarket Approval Application
Business Wire - Thu Mar 27, 6:03AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Nasdaq Stock Market has halted trading of the company's stock.
Correction: DNA Stool Test-FDA story
By MATTHEW PERRONE - AP - Tue Mar 25, 2:27PM CDT
WASHINGTON (AP) — In a story March 24 about colon cancer screening tests, The Associated Press reported erroneously that the Colosure test from LabCorp is approved by the Food and Drug Administration. It has not been approved by the agency. The story also incorrectly stated that another test from Epigenomics is a stool test. It is a blood test.